Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center.

Kajetan Karaszewski, Jakub Góra, Monika Paluszewska, Elżbieta Urbanowska, Ewa Karakulska-Prystupiuk, Piotr Boguradzki, Agnieszka Tomaszewska, Grzegorz Władysław Basak, Wiesław Wiktor Jędrzejczak

Abstract read

PubMed Publisher

In one paragraph

Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kajetan KaraszewskiDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland. kajetan.karaszewski@wum.edu.pl.ORCID https://orcid.org/0009-0006-2112-1698

Jakub GóraDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0009-0003-3299-8143

Monika PaluszewskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.

Elżbieta UrbanowskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.

Ewa Karakulska-PrystupiukDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0002-0201-5041

Piotr BoguradzkiDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0002-3915-1928

Agnieszka TomaszewskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0001-5485-3680

Grzegorz Władysław BasakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0003-3858-8180

Wiesław Wiktor JędrzejczakDepartment of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Ul. Banacha 1A, 02-097, Warsaw, Poland.ORCID http://orcid.org/0000-0002-6813-3331

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantations (allo-HCT) is a procedure with long history and well-documented efficacy in treating various malignant and non-malignant diseases of the hematopoietic system. While there is a potential for late complications even over 10 years following allo-HCT, the data on longer observations are limited due to loss in follow-up, personnel and organizational changes in transplant centers, and focusing on new promising therapies instead of HCT. The study aimed to evaluate 15- and 20-year overall and progression-free survival of allo-HCT recipients in our center. During the inclusion period from 1999 to 2014, we identified 269 allo-HCT recipients. Survival analyses were performed using Kaplan-Meier curves, the Cox proportional hazards model, and the log-rank test. First, we evaluated 15- and 20-year survival rates for the entire cohort of allo-HCT recipients from matched related donor (MRD) and matched unrelated donor (MUD). Then we performed similar analyses for allo-HCT recipients due to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic neoplasms (MDS), non-Hodgkin lymphomas (NHL), and severe aplastic anemia (SAA). It was confirmed that survival benefit continues also during long-term observation. Notably, the plateau effect of PFS was often observed over 20 years following allo-HCT, implying the ability to cure in a relatively large group of patients with otherwise incurable diseases.

Indexed as

Allogeneic transplantationBone marrow transplantationLong-term resultsOverall survivalProgression-free survival

Identifiers

PMID42771262

DOI10.1016/j.beha.2023.101476

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.